drugset / Trial / NCT04205344

Subarachnoid Bupivacaine in Obese Patients Undergoing Cesarean Delivery

NCT04205344 ↗

Phase 4 Completed 40 enrolled Hospital Civil de Guadalajara
RandomizedParallel-groupDouble-blindSupportive care

Summary

This study evaluates the effect of subarachnoid hyperbaric bupivacaine on mean arterial blood pressure (MAP) of pregnant patients with obesity undergoing cesarean section half of the patients will receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg while the other half will receive a dose of 10 mg

Timeline

Start
2017-02-01
Primary completion
2017-06-30
Completion
2018-05-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 5 mg Intrathecal
Subject Bupivacaine Other / unclassified 10 mg Intrathecal

Indications

No indication recorded.